Literature DB >> 19105884

T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India.

M Pai1, R Joshi, S Dogra, A A Zwerling, D Gajalakshmi, K Goswami, M V R Reddy, A Kalantri, P C Hill, D Menzies, P C Hopewell.   

Abstract

BACKGROUND: Interferon-gamma assays (IGRAs) are alternatives to the tuberculin skin test (TST), but IGRA conversions and reversions are not well understood. In a pilot study, we determined conversions and reversions using QuantiFERON-TB Gold In-Tube((R)) (QFT) among household contacts of TB cases, and evaluated the effect of using various definitions and criteria for conversions.
DESIGN: In a cohort of 250 contacts in India, 46% were TST-positive at baseline and 54% were QFT-positive. We re-tested this cohort after 12 months. Conversion rates were estimated using several definitions.
RESULTS: Of the 250 contacts, 205 (82%) underwent repeat testing. Among 85 contacts with baseline TST-negative/QFT-negative results, TST conversion rates ranged between 7.5% and 13.8%, and QFT conversion rates ranged between 11.8% and 21.2%, depending on the definitions used. Among 109 contacts who were QFT-positive at baseline, seven (6.4%) had QFT reversions. QFT reversions were most likely when the baseline TST was negative and QFT results were just above the diagnostic cut-off.
CONCLUSIONS: QFT conversions and reversions occurred among contacts of TB cases. Conversion rates seemed to vary, depending on the test and definitions used for conversions. These findings need to be verified in larger studies in various settings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19105884      PMCID: PMC2951989     

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  41 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak.

Authors:  Katie Ewer; Jonathan Deeks; Lydia Alvarez; Gerry Bryant; Sue Waller; Peter Andersen; Philip Monk; Ajit Lalvani
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

3.  Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts.

Authors:  Inger Brock; Karin Weldingh; Troels Lillebaek; Frank Follmann; Peter Andersen
Journal:  Am J Respir Crit Care Med       Date:  2004-04-15       Impact factor: 21.405

4.  Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing.

Authors:  A Naseer; S Naqvi; B Kampmann
Journal:  Eur Respir J       Date:  2007-06       Impact factor: 16.671

Review 5.  The prognosis of latent tuberculosis: can disease be predicted?

Authors:  Peter Andersen; T Mark Doherty; Madhukar Pai; Karin Weldingh
Journal:  Trends Mol Med       Date:  2007-04-05       Impact factor: 11.951

6.  Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2008-10

7.  Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay.

Authors:  E M S Leyten; C Prins; A W J Bossink; S Thijsen; T H M Ottenhoff; J T van Dissel; S M Arend
Journal:  Eur Respir J       Date:  2007-01-10       Impact factor: 16.671

8.  T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure.

Authors:  Luca Richeldi; Katie Ewer; Monica Losi; Barbara M Bergamini; Pietro Roversi; Jonathan Deeks; Leonardo M Fabbri; Ajit Lalvani
Journal:  Am J Respir Crit Care Med       Date:  2004-05-06       Impact factor: 21.405

9.  T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward.

Authors:  Madhukar Pai; Keertan Dheda; Jane Cunningham; Fabio Scano; Richard O'Brien
Journal:  Lancet Infect Dis       Date:  2007-06       Impact factor: 25.071

10.  Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia.

Authors:  Philip C Hill; Roger H Brookes; Annette Fox; Katherine Fielding; David J Jeffries; Dolly Jackson-Sillah; Moses D Lugos; Patrick K Owiafe; Simon A Donkor; Abdulrahman S Hammond; Jacob K Otu; Tumani Corrah; Richard A Adegbola; Keith P W J McAdam
Journal:  Clin Infect Dis       Date:  2004-03-16       Impact factor: 9.079

View more
  56 in total

Review 1.  Recent advances in testing for latent TB.

Authors:  Neil W Schluger; Joseph Burzynski
Journal:  Chest       Date:  2010-12       Impact factor: 9.410

2.  Effect of Pregnancy on Interferon Gamma Release Assay and Tuberculin Skin Test Detection of Latent TB Infection Among HIV-Infected Women in a High Burden Setting.

Authors:  Sylvia M LaCourse; Lisa M Cranmer; Daniel Matemo; John Kinuthia; Barbra A Richardson; David J Horne; Grace John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

3.  It is high time to reevaluate QuantiFERON-TB gold for clinical practice.

Authors:  Tamara Tuuminen
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

4.  Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes.

Authors:  Madhukar Pai
Journal:  Nat Rev Microbiol       Date:  2010-01-19       Impact factor: 60.633

5.  Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection.

Authors:  David Doberne; Rajiv L Gaur; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

6.  Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers.

Authors:  Felix C Ringshausen; Albert Nienhaus; José Torres Costa; Heiko Knoop; Stephan Schlösser; Gerhard Schultze-Werninghaus; Gernot Rohde
Journal:  Clin Vaccine Immunol       Date:  2011-05-18

7.  Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal.

Authors:  Christian Lienhardt; Katherine Fielding; Abdoul A Hane; Aliou Niang; Cheikh T Ndao; Farba Karam; Helen Fletcher; Fatou Mbow; Jules-François Gomis; Raymond Diadhiou; Roger Diadhiou; Maxime Toupane; Tandakha Dieye; Souleymane Mboup
Journal:  PLoS One       Date:  2010-05-06       Impact factor: 3.240

8.  Serial testing with an interferon-γ release assay in German healthcare workers.

Authors:  Anja Schablon; Melanie Harling; Roland Diel; Felix C Ringshausen; Jose Torres Costa; Albert Nienhaus
Journal:  GMS Krankenhhyg Interdiszip       Date:  2010-09-21

9.  Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers.

Authors:  Felix C Ringshausen; Albert Nienhaus; Anja Schablon; Stephan Schlösser; Gerhard Schultze-Werninghaus; Gernot Rohde
Journal:  BMC Infect Dis       Date:  2010-07-23       Impact factor: 3.090

Review 10.  Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review.

Authors:  Richard N van Zyl-Smit; Alice Zwerling; Keertan Dheda; Madhukar Pai
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.